Division of Colorectal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Surg Endosc. 2018 Jun;32(6):2886-2893. doi: 10.1007/s00464-017-5998-7. Epub 2017 Dec 27.
Quality is the major driver for both clinical and financial assessment. There remains a need for simple, affordable, quality metric tools to evaluate patient outcomes, which led us to develop the HospitAl length of stay, Readmission and Mortality (HARM) score. We hypothesized that the HARM score would be a reliable tool to assess patient outcomes across various surgical specialties.
From 2011 to 2015, we identified colorectal, hepatobiliary, upper gastrointestinal, and hernia surgery admissions using the Vizient Clinical Database. Individual and hospital HARM scores were calculated from length of stay, 30-day readmission, and mortality rates. We evaluated the correlation of HARM scores with complication rates using the Clavien-Dindo classification.
We identified 525,083 surgical patients: 206,981 colorectal, 164,691 hepatobiliary, 97,157 hernia, and 56,254 upper gastrointestinal. Overall, 53.8% of patients were admitted electively with a mean HARM score of 2.24; 46.2% were admitted emergently with a mean HARM score of 1.45 (p < 0.0001). All HARM components correlated with patient complications on logistic regression (p < 0.0001). The mean length of stay increased from 3.2 ± 1.8 days for a HARM score < 2 to 15.1 ± 12.2 days for a HARM score > 4 (p < 0.001). In elective admissions, for HARM categories of < 2, 2-< 3, 3-4, and > 4, complication rates were 9.3, 23.2, 38.8, and 71.6%, respectively. There was a similar trend for increasing HARM score in emergent admissions as well. For all surgical procedure categories, increasing HARM score, with and without risk adjustment, correlated with increasing severity of complications by Clavien-Dindo classification.
The HARM score is an easy-to-use quality metric that correlates with increasing complication rates and complication severity across multiple surgical disciplines when evaluated on a large administrative database. This inexpensive tool could be adopted across multiple institutions to compare the quality of surgical care.
质量是临床和财务评估的主要驱动因素。仍然需要简单、经济实惠、质量指标工具来评估患者的治疗效果,这促使我们开发了 HospitAl 住院时间、再入院率和死亡率(HARM)评分。我们假设 HARM 评分将是评估各个外科专业患者治疗效果的可靠工具。
2011 年至 2015 年,我们使用 Vizient 临床数据库确定了结直肠、肝胆、上消化道和疝手术患者。通过住院时间、30 天再入院率和死亡率计算个人和医院 HARM 评分。我们使用 Clavien-Dindo 分类法评估 HARM 评分与并发症发生率的相关性。
我们确定了 525,083 名外科患者:206,981 例结直肠、164,691 例肝胆、97,157 例疝和 56,254 例上消化道。总体而言,53.8%的患者是择期入院,平均 HARM 评分为 2.24;46.2%的患者是急诊入院,平均 HARM 评分为 1.45(p<0.0001)。所有 HARM 成分与患者并发症的逻辑回归相关(p<0.0001)。对于 HARM 评分<2 的患者,住院时间从 3.2±1.8 天增加到 HARM 评分>4 的患者的 15.1±12.2 天(p<0.001)。在择期入院的患者中,HARM 评分<2、2-<3、3-4 和>4 的患者并发症发生率分别为 9.3%、23.2%、38.8%和 71.6%。在急诊入院的患者中,也存在 HARM 评分增加的类似趋势。对于所有手术类别,无论是否进行风险调整,HARM 评分的增加都与 Clavien-Dindo 分类法所定义的并发症严重程度的增加相关。
HARM 评分是一种易于使用的质量指标,可在大型管理数据库中评估多个外科专业时,与并发症发生率和并发症严重程度的增加相关。这种廉价的工具可以在多个机构中采用,以比较手术治疗质量。